Evidence map›Paper›PMID 42007470›Full record

ArticleTransboundary and emerging diseases2026

Bluetongue Virus Serotype 3 Follow-Up of the 2024 Outbreak in Two Belgian Zoos.

Jonas Spruyt, Laurens Van Mulders, Ilse De Leeuw, Nick De Regge, Barbara Beci, Francis Vercammen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transboundary and emerging diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jonas SpruytCentre for Research and Conservation, Royal Zoological Society of Antwerp, Antwerp, Belgium.ORCID https://orcid.org/0009-0008-2050-6718
Laurens Van MuldersCentre for Research and Conservation, Royal Zoological Society of Antwerp, Antwerp, Belgium.ORCID https://orcid.org/0000-0002-6612-5936
Ilse De LeeuwOperational Direction Infectious Diseases in Animals, Unit of Exotic and Vector-Borne Diseases, Sciensano, Brussels, Belgium, sciensano.be.ORCID https://orcid.org/0009-0005-4028-1841
Nick De ReggeOperational Direction Infectious Diseases in Animals, Unit of Exotic and Vector-Borne Diseases, Sciensano, Brussels, Belgium, sciensano.be.ORCID https://orcid.org/0009-0001-2892-2133
Barbara BeciDepartment of Internal Medicine, Reproduction and Population Medicine, Faculty of Veterinary Medicine, Ghent University, Merelbeke, East Flanders, Belgium, ugent.be.ORCID https://orcid.org/0000-0003-1508-9397
Francis VercammenCentre for Research and Conservation, Royal Zoological Society of Antwerp, Antwerp, Belgium.ORCID https://orcid.org/0000-0001-7064-4758

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In summer 2024, Western Europe experienced extensive outbreaks of bluetongue virus Serotype 3 (BTV-3), a Culicoides-borne orbivirus. Clinical disease was first detected in August 2024 in one of two Belgian zoos, predominantly affecting European bison (

Indexed as

Animals, ZooBluetongueBluetongue virusDisease OutbreaksAnimalsAntibodies, ViralBelgiumBisonSerogroupAntibodies, Viral

Identifiers

PMID42007470
PMCPMC13091090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.